MIR622

Summary

MIR622 (microRNA 622, HGNC:32878) is a microRNA gene on chromosome 13q31.3.

microRNAs (miRNAs) are short (20-24 nt) non-coding RNAs that are involved in post-transcriptional regulation of gene expression in multicellular organisms by affecting both the stability and translation of mRNAs. miRNAs are transcribed by RNA polymerase II as part of capped and polyadenylated primary transcripts (pri-miRNAs) that can be either protein-coding or non-coding. The primary transcript is cleaved by the Drosha ribonuclease III enzyme to produce an approximately 70-nt stem-loop precursor miRNA (pre-miRNA), which is further cleaved by the cytoplasmic Dicer ribonuclease to generate the mature miRNA and antisense miRNA star (miRNA*) products. The mature miRNA is incorporated into a RNA-induced silencing complex (RISC), which recognizes target mRNAs through imperfect base pairing with the miRNA and most commonly results in translational inhibition or destabilization of the target mRNA. The RefSeq represents the predicted microRNA stem-loop.

Source: NCBI Gene 693207 — RefSeq curated summary.

At a glance

• Gene type: non-coding (miRNA) — no protein product; not a drug target. Variant/disease associations are omitted (they would be positional, from an overlapping protein-coding gene).

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:32878
Approved symbol	MIR622
Name	microRNA 622
Location	13q31.3
Locus type	RNA, micro
Status	Approved
Aliases	hsa-mir-622
Ensembl gene	ENSG00000283783
Ensembl biotype	miRNA
Entrez	693207
RNAcentral	URS0000759951 — miRNA, 96 nt, 1 organism(s)

Gene structure

Transcript identifiers

Ensembl transcripts: 1 — 1 miRNA

ENST00000638396

RefSeq mRNA: 0 — MANE Select: None

Canonical transcript exons

ENST00000638396 — 1 exons

Exon	Start	End
ENSE00003803888	90231182	90231277

Expression profiles

Bgee: expression breadth broad, 37 present calls, max score 71.46.

Top tissues by expression

37 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
blood	UBERON:0000178	71.46	gold quality
bone marrow	UBERON:0002371	70.03	gold quality
subcutaneous adipose tissue	UBERON:0002190	69.53	gold quality
Brodmann (1909) area 9	UBERON:0013540	69.36	gold quality
body of stomach	UBERON:0001161	69.08	gold quality
body of pancreas	UBERON:0001150	68.24	gold quality
right ovary	UBERON:0002118	67.92	gold quality
vagina	UBERON:0000996	67.81	gold quality
nucleus accumbens	UBERON:0001882	67.38	gold quality
esophagus mucosa	UBERON:0002469	67.13	gold quality
adult mammalian kidney	UBERON:0000082	67.02	gold quality
transverse colon	UBERON:0001157	66.19	gold quality
gastrocnemius	UBERON:0001388	65.71	gold quality
omental fat pad	UBERON:0010414	64.89	gold quality
left lobe of thyroid gland	UBERON:0001120	62.64	gold quality
small intestine Peyer’s patch	UBERON:0003454	62.64	gold quality
minor salivary gland	UBERON:0001830	62.58	gold quality
pituitary gland	UBERON:0000007	62.47	gold quality
lung	UBERON:0002048	62.24	gold quality
right frontal lobe	UBERON:0002810	62.05	gold quality
hypothalamus	UBERON:0001898	61.90	gold quality
putamen	UBERON:0001874	61.35	gold quality
thyroid gland	UBERON:0002046	61.19	gold quality
adenohypophysis	UBERON:0002196	61.07	gold quality
tibial nerve	UBERON:0001323	59.99	gold quality
tibial artery	UBERON:0007610	59.96	gold quality
prostate gland	UBERON:0002367	59.53	gold quality
skin of leg	UBERON:0001511	59.32	gold quality
caudate nucleus	UBERON:0001873	58.91	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	58.41	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 29)

• Data show that ectopic expression of miR-622 promoted invasion, tumorigenesis and metastasis of gastric cancer cells, and that ING1 is a direct target of miR-622. (PMID:21528065)
• Cell growth retardation was inhibited upon knockdown of K-Ras and an increase in the level of miR-622 in 16HBE-T cells (PMID:22016468)
• Study demonstrates the role of miR-622 in suppressing glioma invasion and migration mediated by ATF2, and shows that miR-622 expression inversely correlates with ATF2 in glioma patients (PMID:25258251)
• K-Ras is the Direct Target of miR-622. MiR-622 inhibited colorectal cancer cells proliferation and migration and tumor metastasis by suppressing K-Ras. (PMID:26333174)
• EZH2/miR-622 promotes hepatoma tumorigenesis through CXCR4 activation. (PMID:26404566)
• miR-622 acts as a tumor suppressor in HCC and restoration of miR-622 may provide therapeutic benefits in the treatment of HCC. (PMID:26467022)
• miR-622 overexpression mediated by the transcription factor FOXO3a decreased the invasiveness of lung tumor cells by inhibiting HIF-1alpha via inactivation of ERK signaling. (PMID:26528854)
• upregulated miRNA-622 inhibited cell proliferation, migration, and invasion via repressing K-Ras in the progression of glioblastoma, and miR-622-K-Ras pathway can be recommended as a potential target for treatment of glioblastoma (PMID:26596833)
• Elevated in the plasma miR-622 could discriminate among Prostate Cancer, Benign Prostatic Hyperplasia, and healthy samples with a high diagnostic performance. (PMID:26806656)
• E2F1 was confirmed as a direct target of miR-622. (PMID:27501502)
• These results indicate a negative link between miR-622 and YAP1 and further confirm that YAP1 is a direct target of miR-622, suggesting that miR-622 could be a new important therapeutic strategy for gliomas treatment. (PMID:28796324)
• Decrease of miR-622 expression promotes the proliferation, migration and invasion of cholangiocarcinoma cells. (PMID:28961507)
• Low miR-622 expression is associated with melanoma. (PMID:29495114)
• miR-320a, miR-622, and miR-429 are possibly novel miRNAs participating in the pathomechanism of gastric MALT lymphoma (PMID:29788729)
• MiR-622 inhibits CRC angiogenesis by suppressing the CXCR4-VEGFA signaling axis. (PMID:30851425)
• plasma SAMMSON has diagnostic value for glioblastoma and SAMMSON overexpression may promote glioblastoma cell proliferation by downregulating miR-622. (PMID:31283714)
• hsa-circ-0000211 promoted lung adenocarcinoma cell migration and invasion by modulating the miR-622/HIF1-alpha network. (PMID:31668923)
• miR-622 is a novel potential biomarker of breast carcinoma and impairs motility of breast cancer cells through targeting NUAK1 kinase. (PMID:32418991)
• Silencing of circular RNA ANRIL attenuates oxygen-glucose deprivation and reoxygenation-induced injury in human brain microvascular endothelial cells by sponging miR-622. (PMID:32616043)
• Identification of novel targets of miR-622 in hepatocellular carcinoma reveals common regulation of cooperating genes and outlines the oncogenic role of zinc finger CCHC-type containing 11. (PMID:33901943)
• MiR-622 acts as a tumor suppressor to induce cell apoptosis and inhibit metastasis in human prostate cancer. (PMID:34231241)
• The expression and function of miR-622 in a variety of tumors. (PMID:34929578)
• Circ_KCNQ5 participates in the progression of childhood acute myeloid leukemia by enhancing the expression of RAB10 via binding to miR-622. (PMID:35413218)
• miR-622 Counteracts the NUAK1-Induced Gastric Cancer Cell Proliferation and the Antioxidative Stress. (PMID:35872695)
• CircUBXN7 suppresses cell proliferation and facilitates cell apoptosis in lipopolysaccharide-induced cell injury by sponging miR-622 and regulating the IL6ST/JAK1/STAT3 axis. (PMID:36257578)
• Associations between KCNQ1OT1 genetic variation rs10766212 and susceptibility to colorectal cancer and clinical stage in a Chinese Han population. (PMID:37349861)
• microRNA-622 upregulates cell cycle process by targeting FOLR2 to promote CRC proliferation. (PMID:38166756)
• Circ_0003855 involvement of esophageal cancer progression through miR-622/FLOT1. (PMID:38686057)
• Hsa-circ-0006091 modulates the proliferation of hepatocellular carcinoma via the miR-622/CCNB1 axis. (PMID:38813026)

Cross-species orthologs

0 orthologs

Protein

Non-coding RNA — no protein product; not a drug target.

Function

No curated pathway, Gene-Ontology, or interaction data.

Disease & clinical

No curated disease, variant, or cancer-driver associations.

Drugs & pharmacology

No drug or pharmacology data — not an established drug target.